Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Economics of Palliative Care for Hospitalized Adults With Serious Illness: A Meta-analysis.

May P, Normand C, Cassel JB, Del Fabbro E, Fine RL, Menz R, Morrison CA, Penrod JD, Robinson C, Morrison RS.

JAMA Intern Med. 2018 Jun 1;178(6):820-829. doi: 10.1001/jamainternmed.2018.0750.

PMID:
29710177
2.

Futility, the Multiorganization Policy Statement, and the Schneiderman Response.

Fine RL.

Perspect Biol Med. 2018;60(3):358-366. doi: 10.1353/pbm.2018.0009.

PMID:
29375065
3.

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.

Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.

Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.

4.

Early experience with digital advance care planning and directives, a novel consumer-driven program.

Fine RL, Yang Z, Spivey C, Boardman B, Courtney M.

Proc (Bayl Univ Med Cent). 2016 Jul;29(3):263-7.

5.

Smad4 loss synergizes with TGFα overexpression in promoting pancreatic metaplasia, PanIN development, and fibrosis.

Garcia-Carracedo D, Yu CC, Akhavan N, Fine SA, Schönleben F, Maehara N, Karg DC, Xie C, Qiu W, Fine RL, Remotti HE, Su GH.

PLoS One. 2015 Mar 24;10(3):e0120851. doi: 10.1371/journal.pone.0120851. eCollection 2015.

6.

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM.

J Clin Oncol. 2015 Apr 20;33(12):1325-33. doi: 10.1200/JCO.2014.57.4244. Epub 2015 Jan 12.

7.

Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.

Sherman WH, Chu K, Chabot J, Allendorf J, Schrope BA, Hecht E, Jin B, Leung D, Remotti H, Addeo G, Postolov I, Tsai W, Fine RL.

Cancer. 2015 Mar 1;121(5):673-80. doi: 10.1002/cncr.29112. Epub 2014 Dec 9.

8.

Cost savings from palliative care teams and guidance for a financially viable palliative care program.

McCarthy IM, Robinson C, Huq S, Philastre M, Fine RL.

Health Serv Res. 2015 Feb;50(1):217-36. doi: 10.1111/1475-6773.12203. Epub 2014 Jul 15.

9.

High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.

Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, Remotti H, Lignelli A, Fine RL.

Neurosurgery. 2014 Apr;74(4):E447-55; discussion E455. doi: 10.1227/NEU.0000000000000251.

PMID:
24226425
10.

Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC.

Dinnen RD, Mao Y, Qiu W, Cassai N, Slavkovich VN, Nichols G, Su GH, Brandt-Rauf P, Fine RL.

Mol Cancer Ther. 2013 Dec;12(12):2792-803. doi: 10.1158/1535-7163.MCT-13-0234. Epub 2013 Oct 14.

11.

Stereotactic radiosurgery plays a critical role in enhancing long-term survival in a patient with pancreatic cancer metastatic to the brain.

Rajappa P, Margetis K, Wernicke G, Ginter P, Cope W, Sherr DL, Lavi E, Fine RL, Schwartz TH, Bruckner H, Pannullo SC.

Anticancer Res. 2013 Sep;33(9):3899-903.

PMID:
24023326
12.

The intensity and frequency of moral distress among different healthcare disciplines.

Houston S, Casanova MA, Leveille M, Schmidt KL, Barnes SA, Trungale KR, Fine RL.

J Clin Ethics. 2013 Summer;24(2):98-112.

PMID:
23923809
13.

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.

Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, Schrope B, Allendorf J, Lee JA, Sherman WH, Chabot JA.

Cancer Chemother Pharmacol. 2013 Mar;71(3):663-70. doi: 10.1007/s00280-012-2055-z. Epub 2013 Jan 31.

PMID:
23370660
14.

The use of fluorescent probes in the study of reactive oxygen species in pancreatic cancer cells.

Dinnen RD, Mao Y, Fine RL.

Methods Mol Biol. 2013;980:321-9. doi: 10.1007/978-1-62703-287-2_18.

PMID:
23359163
15.

Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature.

Gulati AP, Krantz B, Moss RA, Moyal WN, Tsushima DA, Mowatt KB, Schreibman S, Fine RL.

Oncology. 2013;84(3):127-34. doi: 10.1159/000342961. Epub 2012 Dec 8. Review.

PMID:
23235517
16.

The feasibility of real-time in vivo optical detection of blood-brain barrier disruption with indocyanine green.

Ergin A, Wang M, Zhang JY, Bruce JN, Fine RL, Bigio IJ, Joshi S.

J Neurooncol. 2012 Feb;106(3):551-60. doi: 10.1007/s11060-011-0711-5. Epub 2011 Oct 1.

PMID:
21964696
17.

Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan.

Bruce JN, Fine RL, Canoll P, Yun J, Kennedy BC, Rosenfeld SS, Sands SA, Surapaneni K, Lai R, Yanes CL, Bagiella E, DeLaPaz RL.

Neurosurgery. 2011 Dec;69(6):1272-9; discussion 1279-80. doi: 10.1227/NEU.0b013e3182233e24.

18.

Intra-arterial mitoxantrone delivery in rabbits: an optical pharmacokinetic study.

Joshi S, Reif R, Wang M, Zhang J, Ergin A, Bruce JN, Fine RL, Bigio IJ.

Neurosurgery. 2011 Sep;69(3):706-12; discussion 712. doi: 10.1227/NEU.0b013e3182181b67.

19.

The impact of nanoparticle ligand density on dendritic-cell targeted vaccines.

Bandyopadhyay A, Fine RL, Demento S, Bockenstedt LK, Fahmy TM.

Biomaterials. 2011 Apr;32(11):3094-105. doi: 10.1016/j.biomaterials.2010.12.054. Epub 2011 Jan 22.

20.

Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and their structure-activity relationships.

Wang X, Di Pasqua AJ, Govind S, McCracken E, Hong C, Mi L, Mao Y, Wu JY, Tomita Y, Woodrick JC, Fine RL, Chung FL.

J Med Chem. 2011 Feb 10;54(3):809-16. doi: 10.1021/jm101199t. Epub 2011 Jan 11.

21.

The physician's covenant with patients in pain.

Fine RL.

Am J Bioeth. 2010 Nov;10(11):23-4. doi: 10.1080/15265161.2010.520588. No abstract available.

PMID:
21104552
22.

Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics.

Verna EC, Hwang C, Stevens PD, Rotterdam H, Stavropoulos SN, Sy CD, Prince MA, Chung WK, Fine RL, Chabot JA, Frucht H.

Clin Cancer Res. 2010 Oct 15;16(20):5028-37. doi: 10.1158/1078-0432.CCR-09-3209. Epub 2010 Sep 28.

23.

Keeping the patient at the center of patient- and family-centered care.

Fine RL.

J Pain Symptom Manage. 2010 Oct;40(4):621-5. doi: 10.1016/j.jpainsymman.2010.06.008. Epub 2010 Sep 15.

PMID:
20832979
24.

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L.

Cancer. 2011 Jan 15;117(2):268-75. doi: 10.1002/cncr.25425. Epub 2010 Sep 7.

25.

Is it always wrong to perform futile CPR?

Fine RL.

N Engl J Med. 2010 May 27;362(21):2035; author reply 2036-7. No abstract available.

PMID:
20518107
26.

Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.

Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL.

Pituitary. 2011 Dec;14(4):418-24. doi: 10.1007/s11102-009-0211-1.

27.

Point: The Texas advance directives act effectively and ethically resolves disputes about medical futility.

Fine RL.

Chest. 2009 Oct;136(4):963-7. doi: 10.1378/chest.09-1267. No abstract available.

PMID:
19809044
28.

Acute ascending aortic dissection diagnosed with transthoracic echocardiography.

Brunson JM, Fine RL, Schussler JM.

J Am Soc Echocardiogr. 2009 Sep;22(9):1086.e5-7. doi: 10.1016/j.echo.2009.04.006.

PMID:
19733797
29.

Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.

Chabot JA, Tsai WY, Fine RL, Chen C, Kumah CK, Antman KA, Grann VR.

J Clin Oncol. 2010 Apr 20;28(12):2058-63. doi: 10.1200/JCO.2009.22.8429. Epub 2009 Aug 17.

30.

Head and neck squamous cell carcinoma in FAMMM syndrome.

Vinarsky V, Fine RL, Assaad A, Qian Y, Chabot JA, Su GH, Frucht H.

Head Neck. 2009 Nov;31(11):1524-7. doi: 10.1002/hed.21050.

PMID:
19360740
31.

Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.

Schönleben F, Allendorf JD, Qiu W, Li X, Ho DJ, Ciau NT, Fine RL, Chabot JA, Remotti HE, Su GH.

Pancreas. 2008 Mar;36(2):168-72. doi: 10.1097/MPA.0b013e318158a4d2.

32.

Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.

Balmaceda C, Peereboom D, Pannullo S, Cheung YK, Fisher PG, Alavi J, Sisti M, Chen J, Fine RL.

Cancer. 2008 Mar 1;112(5):1139-46. doi: 10.1002/cncr.23167.

33.

Language matters: "sometimes we withdraw treatment but we never withdraw care".

Fine RL.

J Palliat Med. 2007 Dec;10(6):1239-40. No abstract available.

PMID:
18095797
34.

Tackling medical futility in Texas.

Fine RL.

N Engl J Med. 2007 Oct 11;357(15):1558-9; author reply 1559. No abstract available.

35.

Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.

Allendorf JD, Lauerman M, Bill A, DiGiorgi M, Goetz N, Vakiani E, Remotti H, Schrope B, Sherman W, Hall M, Fine RL, Chabot JA.

J Gastrointest Surg. 2008 Jan;12(1):91-100. Epub 2007 Sep 5.

PMID:
17786524
36.

Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance.

Dinnen RD, Drew L, Petrylak DP, Mao Y, Cassai N, Szmulewicz J, Brandt-Rauf P, Fine RL.

J Biol Chem. 2007 Sep 14;282(37):26675-86. Epub 2007 Jul 18.

37.

Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue.

Joshi S, Wang M, Etu JJ, Suckow RF, Cooper TB, Feinmark SJ, Bruce JN, Fine RL.

J Neurooncol. 2008 Jan;86(2):123-32. Epub 2007 Jul 17.

PMID:
17634743
38.
39.

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.

Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot J.

Cancer Chemother Pharmacol. 2008 Jan;61(1):167-75. Epub 2007 Apr 18. Erratum in: Cancer Chemother Pharmacol. 2008 Jan;61(1):177.

PMID:
17440727
40.

Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas.

Lebedeva IV, Washington I, Sarkar D, Clark JA, Fine RL, Dent P, Curiel DT, Turro NJ, Fisher PB.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3484-9. Epub 2007 Feb 21.

41.

Ethical and practical issues with opioids in life-limiting illness.

Fine RL.

Proc (Bayl Univ Med Cent). 2007 Jan;20(1):5-12.

42.

Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors.

Fine RL, Chen J, Balmaceda C, Bruce JN, Huang M, Desai M, Sisti MB, McKhann GM, Goodman RR, Bertino JS Jr, Nafziger AN, Fetell MR.

Clin Cancer Res. 2006 Oct 1;12(19):5770-6.

43.

Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy.

Fine RL, Shah SS, Moulton TA, Yu IR, Fogelman DR, Richardson M, Burris HA, Samuels BL, Assanasen C, Gorroochurn P, Hibshoosh H, Orjuela M, Garvin J, Goldman FD, Dubovsky D, Walterhouse D, Halligan G.

Cancer Chemother Pharmacol. 2007 Mar;59(4):429-37. Epub 2006 Aug 3.

PMID:
16896931
44.

Perioperative immunomodulation with Flt3 kinase ligand or a whole tumor cell vaccine is associated with a reduction in lung metastasis formation after laparotomy in mice.

Carter JJ, Feingold DL, Oh A, Kirman I, Wildbrett P, Stapleton G, Asi Z, Fowler R, Bhagat G, Huang EH, Fine RL, Whelan RL.

Surg Innov. 2006 Mar;13(1):41-7.

PMID:
16708154
45.

PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo.

Michl J, Scharf B, Schmidt A, Huynh C, Hannan R, von Gizycki H, Friedman FK, Brandt-Rauf P, Fine RL, Pincus MR.

Int J Cancer. 2006 Oct 1;119(7):1577-85.

46.

Ethical issues in artificial nutrition and hydration.

Fine RL.

Nutr Clin Pract. 2006 Apr;21(2):118-25. Review.

PMID:
16556921
47.

Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide.

Senatus PB, Li Y, Mandigo C, Nichols G, Moise G, Mao Y, Brown MD, Anderson RC, Parsa AT, Brandt-Rauf PW, Bruce JN, Fine RL.

Mol Cancer Ther. 2006 Jan;5(1):20-8.

48.

Significant reduction of laparotomy-associated lung metastases and subcutaneous tumors after perioperative immunomodulation with flt3 ligand in mice.

Carter JJ, Feingold DL, Wildbrett P, Oh A, Kirman I, Asi Z, Stapleton G, Huang E, Fine RL, Whelan RL.

Surg Innov. 2005 Dec;12(4):319-25.

PMID:
16424952
49.

Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients.

Chen J, Balmaceda C, Bruce JN, Sisti MB, Huang M, Cheung YK, McKhann GM, Goodman RR, Fine RL.

J Neurooncol. 2006 Jan;76(1):85-92.

PMID:
16402278
50.

Medical futility and the Texas Advance Directives Act of 1999.

Fine RL.

Proc (Bayl Univ Med Cent). 2000 Apr;13(2):144-7. No abstract available.

Supplemental Content

Support Center